Loading
JBZ-001 is an experimental oral small-molecule inhibitor from Jabez Biosciences, in phase 1 trials for advanced solid tumours and non-Hodgkin lymphoma.
JBZ-001 is an oral small-molecule inhibitor from Jabez Biosciences. An oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme cells use to make pyrimidine building blocks. Its furthest stage is phase 1, for advanced solid tumours and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.
An oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme cells use to make pyrimidine building blocks. Connects to DHODH.
1.JBZ-001 slips into a pocket on DHODH.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JBZ-001" OR ABSTRACT:"JBZ-001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JBZ-001, not a curated reading list.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/